CSL to acquire Chinese blood plasma fractionator

The Australian blood plasma company buys a majority stake in a Chinese firm for $352 million in hopes of broadening its offering in China. It's the first such deal by a foreign firm.

CSL to acquire Chinese blood plasma fractionator

Australian blood plasma giant CSL is to strengthen its footprint in China with a $352 million deal for an 80 per cent stake in a Chinese plasma factionator.

CSL will acquire the stake in Wuhan Zhong Yuan Rui De Biological Products Ruide from Humanwell Healthcare Group, a Shanghai-listed pharmaceutical company, CSL said in a statement on Tuesday. The deal is subject to regulatory approval.

The deal the first foreign purchase...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: china | health | acquisitions | csl | ruide | australia

Print Edition

FinanceAsia Print Edition